<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02996916</url>
  </required_header>
  <id_info>
    <org_study_id>Olme-brain</org_study_id>
    <nct_id>NCT02996916</nct_id>
  </id_info>
  <brief_title>Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue</brief_title>
  <official_title>Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kurume University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kurume University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertension is a leading risk factor for morbidity and mortality worldwide. The brain is a
      major target of the damaging effects of hypertension. Hypertension has been recognized as the
      leading cause of dementia as well as the most important risk factor for stroke and vascular
      cognitive impairment. Although glucose is the principal cerebral energy source, impact of
      hypertensive treatment on cerebral glucose metabolism is poorly understood.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of treatment on the nominal change in cerebral glucose metabolism from baseline after 6 months of treatment as measured by FDG-PET/CT</measure>
    <time_frame>6 months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in vascular inflammation measured by blood-normalized standardized uptake value, known as a target-to-background ratio (TBR) by FDG-PET/CT</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in abdominal and muscle fat volume as measured by CT</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in circulating inflammatory markers including hsCRP (mg/L), adiponectin (µg/mL), ADMA (nmoL/mL), DPP-4 (ng/mL), advanced glycation end products (AGEs, µg/mL) and angiotensin-(1-7) (ng/mL)</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Efficacy of Olmesartan on Cerebral Glucose Metabolism in Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Olmesartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Olmesartan 10-40mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine 2.5-10mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan</intervention_name>
    <description>10-40mg daily</description>
    <arm_group_label>Olmesartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>2.5-10mg daily</description>
    <arm_group_label>Amlodipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained

          -  Male and female subjects aged 20 years or older at informed consent

          -  Essential hypertension who had never received angiotensin II receptor antagonists and
             calcium channel blockers

        Exclusion Criteria:

          -  Secondary hypertension or malignant hypertension

          -  Diabetes mellitus

          -  History or evidence of a stroke

          -  Hepatic or hematologic abnormality

          -  Mild Cognitive Impairment or Dementia

          -  Serum potassium level ≥ 5.5 mEq/L

          -  Serum creatinine level ≥ 3.0 mg/dL

          -  Acute or chronic disease

          -  Allergy to any drugs

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nobuhiro Tahara, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nobuhiro Tahara, MD, PhD</last_name>
    <phone>+81-942-31-7580</phone>
    <email>ntahara@med.kurume-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Kurume</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nobuhiro Tahara, MD, PhD</last_name>
      <phone>+81-942-31-7580</phone>
      <email>ntahara@med.kurume-u.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Akihiro Honda, MD, PhD</last_name>
      <phone>+81-942-31-7580</phone>
      <email>honda_akihiro@med.kurume-u.ac.jp</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2016</study_first_submitted>
  <study_first_submitted_qc>December 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2016</study_first_posted>
  <last_update_submitted>December 16, 2016</last_update_submitted>
  <last_update_submitted_qc>December 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kurume University</investigator_affiliation>
    <investigator_full_name>Nobuhiro Tahara</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

